NKMAX Receives Clinical Approval for Triple Combination Therapy in Lung Cancer Patients

[Asia Economy Reporter Hyunseok Yoo] NKMAX announced on the 7th that it has completed the approval from the Ministry of Food and Drug Safety for the domestic Phase 1/2a clinical trial of a triple combination therapy. With this, NKMAX is currently conducting a total of seven clinical trials: two in Korea, three in the United States, and two in Mexico.

The newly added clinical trial targets non-small cell lung cancer (NSCLC) patients who have failed TKI (Tyrosine kinase inhibitor) treatment. The trial is planned to be conducted at a hospital in Seoul. Currently, there is no suitable treatment option for patients who fail TKI therapy. TKIs are representative first-line treatments for NSCLC, functioning as drugs that inhibit the activity of tyrosine kinase proteins which promote cancer cell growth.

This clinical trial will involve a total of 24 patients, initially divided into four cohorts, receiving a combination of SuperNK (SNK01), GC (Gemcitabine Carboplatin), and Erbitux (active ingredient: Cetuximab).

▲ Cohorts 1 and 3, consisting of 12 patients, will receive a combination of SuperNK (4 billion and 6 billion cells) and GC, while ▲ Cohorts 2 and 4, also 12 patients, will receive a triple combination of SuperNK (4 billion and 6 billion cells), GC, and Erbitux. ▲ The occurrence of Dose Limiting Toxicity (DLT) will determine whether Cohorts 5 and 6 will proceed.

This trial aims to evaluate the safety and efficacy of the combined administration of SuperNK with chemotherapy and targeted therapy.

Yongman Kim, Director of Research at NKMAX, stated, “Currently, there is no standard treatment for NSCLC patients who have developed resistance to TKI,” adding, “Based on previous lung cancer clinical trials confirming the therapeutic potential of SuperNK for these patients, we decided to proceed with this trial.” He further noted, “We hope to provide a new anticancer treatment opportunity with SuperNK for NSCLC patients who have no standard treatment options.”